Protagonist Therapeutics, Inc

For the period ended Dec 31, 2025. Filed Feb 25, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 25, 2026

PTGX$135.90+2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except share data)


· · December 31,
· · 2025 · · 2024
Assets
Current assets:
Cash and cash equivalents	$128,390	$97,249
Marketable securities	438,974	321,664
Receivable from collaboration partner	121	165,000
Prepaid expenses and other current assets	10,089	7,728
Total current assets	577,574	591,641
Marketable securities - noncurrent	78,638	140,252
Property and equipment, net	3,860	3,190
Restricted cash - noncurrent	287	225
Operating lease right-of-use asset	7,829	9,417
Total assets	$668,188	$744,725
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$5,339	$1,615
Accrued expenses and other payables	28,269	23,693
Deferred revenue	9,550	18,891
Income taxes payable	—	2,689
Operating lease liability	2,283	510
Total current liabilities	45,441	47,398
Deferred revenue - noncurrent	—	11,676
Operating lease liability - noncurrent	8,040	10,356
Total liabilities	53,481	69,430
Commitments and contingencies (Note 9)
Stockholders’ equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized; no shares issued and outstanding	—	—
Common stock, $0.00001 par value, 180,000,000 shares authorized; 62,577,897 and 61,035,139 shares issued and outstanding as of December 31, 2025 and 2024, respectively	1	1
Additional paid-in capital	1,084,736	1,015,898
Accumulated other comprehensive income (loss)	641	(82)
Accumulated deficit	(470,671)	(340,522)
Total stockholders’ equity	614,707	675,295
Total liabilities and stockholders’ equity	$668,188	$744,725

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.